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We previously showed that B cell receptor associated protein 31(BAP31) was significantly upregulated in colorectal cancer com-
pared with normal mucosa epithelia. However, its expression pattern and pathological role in colorectal cancer are not clearly 
understood. In this study, we investigated whether the expression of BAP31 was associated with the clinicopathological parame-
ters of colorectal cancer. The expression pattern of BAP31 was detected by immunohistochemistry on a tissue microarray in both 
primary tumor and paired distant normal mucosa samples from 120 consecutive colorectal cancer patients. Furthermore, BAP31 
protein expression was also determined in twenty colorectal adenomas and eight liver metastasis samples. There was positive 
expression of BAP31 in 64.17% of primary tumors and 6.67% in distant normal mucosa (P=0.000). Negative expression of 
BAP31 was correlated with distant metastasis (P=0.036) and lower tumor differentiation grade (P=0.001). Patients with 
BAP31-negative expression showed significantly lower overall survival rate (P=0.003) compared to patients with BAP31-positive 
expression. Our results demonstrate that BAP31 may serve as a candidate prognostic marker in colorectal cancer and negative 
BAP31 expression may lead to more aggressive invasion of colorectal cancer. 
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Colorectal cancer is the third most lethal disease worldwide 
[1]. A large number of new cases and deaths occur every 
year because of the expanding and aging of population, in 
both developed and developing countries [2,3]. Great pro-
gress had been made in treating colorectal cancer in recent 
years. However, most patients are diagnosed after the ap-
pearance of invasive cancer, which restricts further attempts 
to improve the survival rate [4]. If the cancer can be detect-
ed at an earlier stage, the number of deaths will be reduced. 
Consequently, there is an urgent need for candidate bi-
omarkers to assist in the early detection and prognostication 
of colorectal cancer.  
Our previous study found potential protein markers of 
colorectal cancer by an acetylation stable isotopic labeling 
method coupled with linear quadrupole ion trap Fourier 
transform mass spectrometry (LTQFTMS). A total of 137 
proteins were deemed to be significantly upregulated or 
downregulated in cancer by virtue of an at least two-fold 
difference in protein expression levels between microdis-
sected tumor cells and normal mucosa tissues [5]. Among 
those proteins, BAP31 was upregulated over four-fold in 
colorectal cancer tissues compared to distant normal muco-
sa. Thus, we detected the expression of BAP31 in 120 pa-
tients who have experienced a surgery for colorectal cancer.  
BAP31 was initially identified as B cell receptor associ-
ated protein 31 by Kim et al. [6] in 1994, and is a member 
of a B cell receptor protein family associated with mem-
brane immunoglobulin D (mIgD). The full length BAP31 
protein is involved in the activation of B cells. Some studies 
have shown BAP31 to be an important mediator of the  
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trafficking of membrane proteins and a regulator of apopto-
sis [7,8]. BAP31 is located at the endoplasmic reticulum 
(ER) where it is cleaved to BAP20, which has a crucial role 
in apoptosis [9,10]. Additional studies showed that BAP31 
is involved in ER-stress-mediated apoptosis, which depends 
on calnexin binding to BAP31 in tumor cells [11]. Recent 
studies also indicated that BAP31 is a Bcl-2-binding protein 
that could activate the Bcl-2 antagonists Bax or Bak, which 
could promote apoptosis [12]. The cell death-related calre-
ticulin exposure pathway could be interrupted by knock-in 
mutation of BAP31, which was uncleavable by caspase-8 
[13]. A striking feature of cancer cells is that they do not 
undergo apoptosis. Abnormalities in apoptotic function 
contribute to the pathogenesis of colorectal cancer [14]. A 
feature of apoptosis in the intestine is that colonic epithelial 
cells appear to be highly resistant to apoptosis [15]. These 
findings suggest that BAP31 may play a critical role in tu-
morigenesis in human tumors, including colorectal cancer.  
To date, the expression pattern of BAP31 in colorectal 
cancer is unclear. In this study, we detected the expression 
of BAP31 in a large series colorectal cancer samples, and 
examined whether BAP31 expression correlated with clini-
copathological features of colorectal cancer as a clinical 
information index. 
1  Patients and methods 
(i) Patients.  A total of 120 consecutive colorectal cancer 
patients were included in this study. The patients had un-
dergone surgical resection without preoperative chemo-
therapy or radiotherapy in the department of Gastroentero-
logical Surgery at Peking University People’s Hospital be-
tween September 2002 and April 2004. Primary cancer and 
paired distant normal mucosa specimens were taken from 
the resections of all patients and determined by pathology. 
Tissue samples from 20 colorectal adenomas and 8 liver 
metastases were also investigated in this study. The main 
clinicopathological characteristics are shown in Table 1.  
Clinical follow-up data were available for 103 patients 
and 17 patients were lost to follow-up. The mean follow-up 
time of patients still alive at the end of the analysis
Table 1  Association between clinicopathological data and immunoreactivity for BAP31 in 120 colorectal cancer samplesa) 
 
n 
BAP31 expression 2 P 
 BAP31+ BAP31 
Tissue      
Tumor samples  77 43 86.728 0.000* 
Distant normal tissue  8 112  
Gender     
Male 74 49 25 0.353 0.553 
Female 46 28 18  
Tumor location     
Colon 75 47 28 0.002 0.961 
Rectum 45 28 17  
Differentiation     
Poorly 21 7 14 10.525 0.001* 
Moderately or well 99 70 29  
TNM classification     
I 11 8 3 2.596 0.458 
II 43 28 15  
III 44 30 14  
IV 22 11 11  
Depth of wall invasion     
T1+T2 19 15 4 2.145 0.143 
T3+T4 101 62 39  
Lymph node metastasis     
No 55 38 18 0.622 0.430 
Yes 64 39 25  
Distant metastasis     
M0 96 66 30 4.385 0.036* 
M1 24 11 13   
a) Statistical analysis was conducted by Pearson’s chi-square test. *, P<0.05. P values less than 0.05 were considered significant. 
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was 53.3 months (range, 1–78 months). By the end of the 
study, 43 of 120 patients had died. Three of them died from 
non-tumor diseases (pneumonia, myocardial infarction, and 
diabetes). This study was approved by the Ethics Commit-
tee of Peking University People’s Hospital. 
(ii) Tissue microarray construction.  The tissue micro-
arrays were constructed with two replicated cores for each 
of colorectal case. Core tissue biopsies (2 mm in diameter) 
were taken from formalin fixed paraffin-embedded tumor 
samples and distant normal mucosa. These blocks were ar-
ranged in a new recipient paraffin block (tissue array block) 
using a commercially available microarray instrument 
(Beecher Instruments, Micro-Array Technologies, Silver 
Spring, MD). Eleven tissue array blocks were prepared, 
which contained 10–12 matched sample cores from the 120 
coupled tumor and distant normal mucosa. Another tissue 
array contained 20 colorectal adenoma samples with only 1 
core and 8 liver metastasis samples with replicated cores. 
To qualify for this study, a case needed to have a tumor 
occupying more than 10% of the core tissue area. Clinical 
and pathological information for this group of patients was 
obtained by review of histopathology reports and medical 
records. 
(iii) Immunohistochemistry.  The tissue sections on the 
tissue microarray (4 m) from the surgical specimens were 
stained for BAP31 expression using immunohistochemistry. 
These sections were deparaffinized with a xylene rinse and 
then transferred through two changes of 100% ethanol. The 
sections were then placed in boiling sodium citrate buffer 
(pH 6.8) for 15 min to retrieve the masked epitopes. After 
antigen retrieval, the sections were incubated with the pri-
mary antibody (1:400 dilution of BAP31 antibody [Genetex 
Inc, USA]) at room temperature for 2 h. The primary anti-
body was replaced by phosphate buffer solution (PBS) (pH 
7.4) in the negative control. According to the manufactur-
er’s instructions of the Envison Detection Kit (Gene Tech, 
Shanghai), the sections were incubated with the Chem-
Mate™ Envision/HRP reagent at room temperature for 30 
min. Diaminobenzidine (DAB) was used as a chromogen.  
(iv) Scoring.  Immunohistochemistry scoring was per-
formed by a pathologist and a researcher. Immunoreactivity 
was evaluated using a semiquantitative scoring system 
[16,17], taking into account the percentage positivity of 
tumor cells and staining intensity. Positivity was seen as a 
brown reaction product staining the cytoplasm. Thus, they 
were scored as negative or positive and the areas of the 
staining were recorded, which ranged from 0–100%. The 
area of staining was graded as following: 0, no staining or 
<5% stained positive tumor cells; 1, 5%–25% stained posi-
tive; 2, 26%–50% stained positive; 3, 51%–75% stained 
positive; 4, >75% stained positive. The staining intensity 
was recorded as 0=negative, 1=weak, 2=moderate staining, 
and 3=strong staining. The final score was obtained as fol-
lows: Immunohistochemistry Score = Percentage of Positive 
Tumor Cells  Staining Intensity Score. Theoretically, the 
scores could range from 0 to 12. Subsequently, scores were 
divided in a 2-tiered system to distinguish negative (scores 
0), positive (scores 1–12) scores.  
(v) Statistical analysis.  All statistical analyses were 
performed with SPSS 13.0 software (SPSS Inc, Chicago, 
USA). The Pearson’s chi-square and Fisher exact test were 
used to test the significance of the differences in BAP31 
expression between two groups for categorical variables. 
Survival curves of colorectal cancer patients after surgery 
were estimated by Kaplan-Meier method. Log-rank test was 
used to evaluate the differences of the curves. A P value of 
0.05 or less was considered significant. 
2  Results 
2.1  Clinical characteristics of patients with colorectal 
cancer 
There were 74 (61.67%) men and 46 (38.33%) women, with 
a median age of 64.5 years (range 26 to 89 years). The site 
of tumor was the colon in 75 (62.50%) patients and the rec-
tum in 45 (37.50%) patients. The clinicopathological fea-
tures of these 120 tissues samples are shown in Table 1. 
2.2  Immunohistochemical detection of BAP31 
expression 
We used an immunohistochemistry assay to validate the 
expression of BAP31 in normal mucosa and in primary  
tumors. BAP31 showed an intracellular origin and distribu-
tion. BAP31 staining was negative or weak in normal mu-
cosal epithelia cells (Figure 1(b), (d) and (f)), but stronger in 
tumor cells (Figure 1(a), (c) and (e)). BAP31 staining was 
negative in normal tissue abutting strongly stained tumor 
tissue (Figure 1(h)). The distribution of BAP31 staining in 
primary tumor and paired distant normal mucosa is summa-
rized in Table 1. Results from the tissue assay showed that 
64.17% of colorectal cancer samples showed positive stain-
ing for BAP31 compared with only 6.67% of the distant 
normal mucosa. BAP31 expression increased from distant 
normal mucosa to primary tumor (P=0.000).  
We also examined the expression of BAP31 in eight  
liver metastases and twenty colorectal adenoma samples. 
The staining of BAP31 was negative or weak in these  
tissues. BAP31 expression is dramatically down-      
regulated  in these samples compared with primary tu-
mors (Table 2, Figure 2).  
2.3  Clinicopathological significance of BAP31  
expression in colorectal cancer 
We investigated 120 paired samples by immunohistochem-
istry, and there were no differences in BAP31 expression in 
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Figure 1  Immunohistochemical staining for BAP31 expression in tissue specimens of colorectal cancer (a, c, and e) and paired normal mucosa epithelia (b, 
d and f). Positive staining in tumor cells: weak (a), moderate (c), and strong staining (e); Negative staining or weak staining in normal mucosa epithelia (b, d 
and f); Negative staining in colorectal cancer (g); Positively stained colorectal cancer cells and abutting negative normal mucosa epithelia (h). Original mag-
nification  100. 
primary tumor according to clinicopathological variables, 
including gender, site of tumor, lymph node metastasis, 
TNM (tumor node metastasis) stages, and depth of wall 
invasion (P>0.05). BAP31 positive-expression in moder-
ately and well differentiation tumor cells was significantly 
more frequent than in poorly differentiated cells (P=0.001). 
BAP31 expression in tumors without distant metastasis was 
also significantly more frequent compared with that in tu-
mors with distant metastasis (P=0.036).  
2.4  Positive expression of BAP31 was an indicator of 
better prognosis of colorectal cancer  
The overall survival rates of BAP31 negative and positive 
expression patients with colorectal cancer were 42.3% and 
67.3%, respectively. The mean survival was 58.4 months in 
BAP31-positive patients compared to 40.9 months for the 
BAP31-negative patients. The median survival was 28 
months in the BAP31-negative group but could not be
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Figure 2  Immunohistochemical detection of BAP31 in tissue specimens. Negative staining in adenoma (b) and liver metastasis (a) of the colon. Original 
magnification  100. 
Table 2  BAP31 protein expression in liver metastasis tumors of colorectal cancer and colorectal adenoma a) 
Tissue n 
BAP31 expression 2 P 
BAP31+ BAP31 
Tumor samples 120 77 43   
Adenoma samples 20 2 18 20.457 0.000* 
Liver metastasis samples 8 1 7  0.006** 
a) *, Tumor samples vs. adenoma samples. **, Tumor samples vs. liver metastasis samples. Statistical analysis was conducted by Pearson’s chi-square 
test and Fisher exact test. P values less than 0.05 were considered significant. 
 
estimated in BAP31-positive group. The overall survival 
curve showed that the overall survival rate was significantly 
increased in the group with positive BAP31 expression   
when compared with the BAP31-negative group (P=0.003, 
Figure 3). 
3  Discussion 
BAP31 is a polytopic integral protein that is located in the 
endoplasmic reticulum membrane. As a member of the 
B-lymphocyte receptor associated protein family it can bind 
membranous immunoglobulin to activate B-lymphocytes  
 
 
Figure 3  Kaplan-Meier survival curves for colorectal cancer patients 
categorized by expression of BAP31. Survival rate was significantly lower 
in patients with BAP31 negative expression than those in positive expres-
sion (P=0.003). The P-value was determined using a log-rank test. 
[18]. Some studies showed that overexpression of BAP31 
increases the cell surface level of class I major histocom-
patibility complex (MHC) molecules [19]. BAP31 is very 
important in general cell processes including early secretory 
pathway trafficking of proteins and regulating the export of 
selected membrane proteins to the Golgi apparatus [18,20]. 
Additionally, as a mediator of apoptosis, full-length BAP31 
acts as an inhibitor of apoptosis. It is a preferred substrate of 
caspase-8 and is cleaved within its cytosolic domain to gen-
erate proapoptotic BAP20, which contributes to apoptosis 
[8,9,21]. Calnexin’s regulation of ER-stress-mediated 
apoptosis depends on its binding to BAP31 [11]. In solid 
tumor cells, generation of the BAP20 caspase-8 cleavage 
fragment of BAP31 also directs a proapoptotic signal in the 
action of edelfosine [22].  
Although BAP31 RNA is ubiquitous [23], the protein is 
limited to T- and B-lymphocytes, the thymus, some germ 
cells (such as follicular cells), and some activated gland 
epithelia [20]. The function of BAP31 in cancer is not clear, 
and reports on the relationship between BAP31 and cancer 
are rare. This is the first report of BAP31 expression in col-
orectal cancer in a large number of patients. In the present 
study, we confirmed the elevated expression of BAP31 in 
colorectal cancer compared with distant normal mucosa, 
which had been noted in our previous study [5]. That study 
identified BAP31 as a colorectal cancer-related protein by 
proteomics technology. In present study, BAP31 protein 
was more frequently expressed in primary tumors than in 
paired normal mucosa. The staining in most of normal tis-
sues and adenomas were negative or weak. BAP31 is also 
strongly expressed in well-differentiated carcinoma, but  
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weakly or negatively in poorly differentiated tumor cells. It 
also showed weak staining in liver metastasis. These dif-
ferent expressions may indicate that BAP31 plays a role in 
the development of colorectal cancer. Immunohistochemis-
try showed that BAP31 was located in the cytoplasm of 
colorectal cells. Thus, BAP31 may be involved in biological 
activities of cancer cells, such as protein transport and 
apoptosis. Increased expression of BAP31 was also corre-
lated with well-differentiated and non-metastatic tumors, 
but not with clinical TNM stage. The results suggested that 
BAP31 was a marker of tumor differentiation. Positive ex-
pression of BAP31 is associated with better overall survival, 
and that BAP31 might have a pro-apoptosis function in the-
se tumors. The results suggest that the high levels of BAP31 
lead to high levels of cleavage to generate the proapoptotic 
BAP20 fragment. The exact mechanism of the action of 
BAP31 in these tumors remains unclear. 
Patients with BAP31 negative expression had a signifi-
cantly shorter survival after surgery compared with patients 
who had positive expression. We also noted that patients 
with metastasis were more likely to be negative for BAP31 
expression. Thus, we suggest that upregulation of BAP31 
may contribute to preventing tumor invasion in colorectal 
cancer. Negative BAP31 expression was associated with 
aggressive tumor behaviors. 
In conclusion, the highly frequent expression of BAP31 
in primary colorectal cancer, but not in normal tissues, was 
demonstrated, for the first time, in the present study. Nega-
tive BAP31 expression was significantly associated with 
poor differentiation, distant metastasis and lower overall 
survival rate. It is important to identify prognostic factors 
for patients with colorectal cancer because of their poor 
prognosis. Although further studies are needed to confirm 
the precise function of BAP31 in colorectal cancer, we 
suggest that BAP31 could be a potential prognostic marker 
in this tumor.  
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